Initial weight reductions often include water loss and decreased bloating from reduced food intake, followed by gradual fat loss
Glucagon-Like Peptide 1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus. Edited by David M Nathan and Katya Rubinow, UpToDate, Wolters Kluwer, 9 Nov
These injections are commonly used to manage type 2 diabetes and have been approved for weight loss in certain individuals
Summary Background Amycretin is a novel unimolecular glucagon-like peptide-1 (GLP-1) and amylin receptor agonist
In the last 5 years Agnieszka Jakubowska conducts trials funded by: Eli Lilly, NewAmsterdam, and Novo Nordisk
The relative benefits of metformin compared with the other classes of diabetes medications with cardiovascular benefit are unlikely ever to be established in view of the size, length and cost of any trial that would be required, especially for a drug that is generic